360 filings
Page 5 of 18
8-K
oje116d7ffxu14p86uc
7 Aug 18
Dynavax Reports Second Quarter 2018 Financial Results
12:00am
8-K
47hijq2mnq0ed0na
5 Jun 18
Other Events
12:00am
8-K
z1wqdwl6w0 6bvm1rx9
1 Jun 18
Departure of Directors or Certain Officers
4:50pm
8-K
9lfzo9np65l 2cld
9 May 18
Dynavax Reports First Quarter 2018 Financial Results
4:10pm
8-K
82k37 nv6ul6dp
26 Apr 18
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
4:10pm
8-K
2orj5v3 53
18 Apr 18
Other Events
12:00am
8-K
blcyvm3aopim3xq6wq7h
8 Mar 18
Dynavax Reports Fourth Quarter and Year End 2017 Financial Results
12:00am
8-K
4itpioy8 zz
2 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
3kx0h8bzfwot8fe1axaa
22 Feb 18
HEPLISAV-B is the First and Only Two-Dose Vaccine in the U.S. for Hepatitis B Prevention in Adults
12:00am
8-K
fsm3zwtlnb3
20 Feb 18
Dynavax Secures $175 Million inNon-Dilutive Debt Financing
12:00am
8-K
oz50rh7r
9 Jan 18
Dynavax Announces HEPLISAV-B™ is Now Available in the United States
12:00am
8-K
3eoxhy
5 Jan 18
Results of Operations and Financial Condition
12:00am
8-K
d8ey 7mudu69g
30 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
90ukr8no
14 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
i2hl971
3 Nov 17
Dynavax Reports Third Quarter 2017 Financial Results
12:00am
8-K
rbq03zo3eipopvhx1
1 Sep 17
Other Events
12:00am
8-K
nj7emai8a
10 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
g93s2gob
7 Aug 17
Dynavax Provides U.S. Regulatory Update onHEPLISAV-B™ Following FDA Advisory Committee Meeting
12:00am
8-K
i2t6i5 8xj
2 Aug 17
Dynavax Reports Second Quarter 2017 Financial Results
12:00am
8-K
vvx03 j75g
31 Jul 17
Dynavax Announces FDA Advisory Committee
12:00am